ARC TALKS
WEBINAR SERIES

ATTR Clinical Trials (July 2026)

July 22 | 12pm - 1pm ET

Kristen Hsu

Executive Director of Research
Amyloidosis Research Consortium

About ARC

Amyloidosis Research Consortium

ARC's mission is to improve and extend the lives of those with amyloidosis



ARC Talks Supported By

Amyloidosis Research Consortium

ALEXION

Alnylam® PHARMACEUTICALS

AstraZeneca

BRIDGEBIO

Intellia THERAPEUTICS

novo nordisk®

Orsini Rare Disease Pharmacy Solutions

Pfizer

protego

REGENERON

Before We Begin

Amyloidosis Research Consortium

This webinar is recorded. We will post the webinar on our website so you can view it again later.

Submit your questions anytime via the Q&A box. We will try to answer them at the end.

If you are having trouble with the audio using your computer, you can dial in (check your email for info).

ATTR Amyloidosis Booklets

Amyloidosis Research Consortium



arci.org/booklets

ARC TALKS
WEBINAR SERIES

ATTR Clinical Trials (July 2026)

July 22 | 12pm - 1pm ET

Kristen Hsu

Executive Director of Research
Amyloidosis Research Consortium

If you are here to learn about AL clinical trials…

…check out our November webinar focusing on AL amyloidosis clinical trials on our website or YouTube channel.
Our next AL amyloidosis clinical trials webinar is planned for November 2026

arci.org/webinars



youtube.com/@Amyloidosis_ARC



What is a Clinical Trial?

Amyloidosis Research Consortium

- A clinical study is research study involving human volunteers (also called participants) that is intended to add to medical knowledge.
- There are two types of clinical studies: interventional studies (also called **clinical trials**) and observational studies.

Interventional

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. The assignments are determined by the study's protocol. Participants may receive diagnostic, therapeutic, or other types of interventions.

Observational

A type of clinical study in which participants are identified as belonging to study groups and are assessed for biomedical or health outcomes. Participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to a specific interventions/treatment.

Clinicaltrials.gov/study-basics/glossary

Clinical Trial Phases

- Trials are divided into different stages, called phases.
- Each trial phase has a specific purpose and is designed to answer certain questions:

Phase 1	Phase 2	Phase 3	Phase 4
Determines a safe dose of the treatment under study (study drug) and monitors how the new treatment affects the human body (i.e. how the drug is broken down and excreted by the body).	Gather preliminary data on whether the new treatment works in people who have a certain condition/disease and continues to evaluate safety.	Confirms how well a treatment works, monitors side effects, and compares the new treatment with the current standard treatment or a control arm in a randomized controlled study.	Post regulatory approval, gathers more information on a drug or treatment after it has been marketed to see its effect in various populations and any side effects associated with long-term use.

- The pathway develop a new drug is not always linear. This is especially true in rare disease!

Investigative approaches to treating ATTR Amyloidosis..!

Amyloidosis Research Consortium



…are like treating a filling bathtub



Slow down or even stop the production of amyloid (turning off the faucet)

Remove existing amyloid (draining a filling tub)

Ideal scenario would be turning off the faucet and draining the tub

Novel Approaches to Treat ATTR Amyloidosis

Amyloidosis Research Consortium

Knockdown of TTR

- Patisiran (Onpattro) for hATTR-PN
- Inotersen (Tegsedi) for hATTR-PN (discontinued in US)
- Vutrisiran (Amvuttra) for hATTR-PN and ATTR-CM
- Eplontersen* (Wainua) for hATTR-PN
- Nexiguran ziclumeran (nex-z, NTLA-2001)
- Nucresiran

*Investigational for ATTR-CM

TTR Stabilizers

- Tafamidis (Vyndamax) for ATTR-CM
- Acoramidis* (Attruby) for ATTR-CM
- Diflunisal
- Tolcopone

*Investigational for ATTRv gene carriers

Anti-fibril agents

- Coramitug (NNC6019-0001)
- Cliramitug (ALXN2220)
- TBD (BridgeBio)



ATTR Amyloidosis Clinical trials

Changes in Novel ATTR Therapies since January 2026

Amyloidosis Research



TTR Stabilizers	Pfizer	Tafamidis CM (Vyndaqel/Vyndamax)	Approved
	BridgeBio	Acoramidis (Attruby) CM	Approved
		Acoramidis ATTRv Carriers	P3 Recruiting
	Corino	Tolcapone	P1 Complete
Knockdown TTR	Alnylam	Patisiran (Onpattro) PN	Approved
		Vutrisiran (Amvuttra) PN	Approved
		Vutrisiran (Amvuttra) CM	Approved
		Nucresiran CM	P3 Recruiting
		Nucresiran PN	P3 Recruiting
	~~Ionis~~	~~Inotersen (Tegsedi) PN~~	~~Approved~~
	Ionis / AZ	Eplontersen (Wainua) PN	Approved
		Eplontersen CM	**P3 Primary Endpoint not met**
	Intellia	Nex-z (NTLA-2001) CM	P3 Recruiting
		Nex-z (NTLA-2001) PN	P3 Recruiting
Anti-fibril agents	Novo Nordisk	Coramitug CM (fka NNC6019-0001)	P3 Recruiting
	Alexion/ AZ	Cliramitug CM (fka ALXN2220, NI006)	P3 results 2027
	BridgeBio	Depleter (TBD)	P1 expected 2027-2028

Last Update July 2026

CARDIO-TTRansform (eplontersen; gene silencer)

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care
Primary endpoint	Assess whether treatment with eplontersen improves outcomes of cardiovascular mortality and recurrent cardiovascular events compared to placebo
Number of patients	1438
Study Drug	Subcutaneous (under the skin) injection every 4 weeks
Chance of receiving study drug?	1:1 eplontersen to placebo
How long?	140 weeks (2.69 years)
Timeframe	March 2020 to April 2026

CARDIO-TTRansform (eplontersen; gene silencer) RESULTS

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

Overall result	**The trial did not meet its primary endpoint.** Adding eplontersen to standard care did not significantly lower the combined risk of cardiovascular death and repeat cardiovascular events, compared with placebo.
Safety	Eplontersen was **generally well tolerated**, with side effects similar to what's been seen in earlier studies. No new safety concerns were reported.
Subgroup finding	**In a pre-planned subgroup (the ~4 in 10 participants not on a TTR stabilizer) eplontersen alone showed a "nominally significant" result.** No added benefit was seen in those already on a stabilizer.
What we still don't know	• How many cardiovascular deaths and hospitalizations occurred in each group • Results on other measures, like walking distance, quality of life, and survival overall • Whether benefit (or lack of it) differed for people with hereditary vs. wild-type ATTR-CM, or by disease stage • More detail on the no-stabilizer subgroup, and whether that finding holds up and is clinically meaningful
When we'll know more	Full trial results are expected at the European Society of Cardiology (ESC) Congress in **August 2026**

Recruiting Trials for Novel ATTR Therapies in 2026

Amyloidosis Research



TTR Stabilizers	Pfizer	Tafamidis CM (Vyndaqel/Vyndamax)	Approved
	BridgeBio	Acoramidis (Attruby) CM	Approved
		Acoramidis ATTRv Carriers	**P3 Recruiting**
	Corino	Tolcapone	P1 Complete
Knockdown TTR	Alnylam	Patisiran (Onpattro) PN	Approved
		Vutrisiran (Amvuttra) PN	Approved
		Vutrisiran (Amvuttra) CM	Approved
		Nucresiran CM	**P3 Recruiting**
		Nucresiran PN	**P3 Recruiting**
	~~Ionis~~	~~Inotersen (Tegsedi) PN~~	~~Approved~~
	Ionis / AZ	Eplontersen (Wainua) PN	Approved
		Eplontersen CM	P3 Primary Endpoint not met
	Intellia	**Nex-z (NTLA-2001) CM**	**P3 Recruiting**
		Nex-z (NTLA-2001) PN	**P3 Recruiting**
Anti-fibril agents	Novo Nordisk	**Coramitug CM (fka NNC6019-0001)**	**P3 Recruiting**
	Alexion/ AZ	Cliramitug CM (fka ALXN2220, NI006)	P3 results 2027
	BridgeBio	Depleter (TBD)	P1 expected 2027-2028

Last Update July 2026

ACT-EARLY (acoramidis; TTR stabilizer)

Asymptomatic carriers of TTR mutations

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Determine whether treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of disease
Primary endpoint	Assess whether treatment with acoramidis delays time to development of ATTR-CM (through biopsy or imaging-based diagnosis) or ATTR-PN (through onset of new signs or symptoms and biopsy-based diagnosis
Key eligibility criteria	- Asymptomatic carriers of a known pathogenic TTR gene variant - 18 to 75 years old - Age is within 10 years of predicted age of disease onset or older based either on family history or published literature (if family history is insufficient or unknown)
Number of patients	587
Study Drug	Daily tablets, twice a day
Chance of receiving study drug?	1/2 (50% chance) will receive acoramidis
How long?	Up to 7 years
Website	https://clinical-trials.bridgebio.com/

Recruiting Global ACT-Early Countries (as of 7/22/26)

Amyloidosis Research Consortium

Recruiting ACT-Early US Centers (as of 7/22/26)

Amyloidosis Research Consortium

Recruiting Centers:

- **California-** Stanford, La Jolla, Los Angeles, San Francisco
- **Colorado-** Aurora
- **Connecticut-** New Haven
- **District of Columbia-** Washington
- **Florida-** Jacksonville, Weston
- **Georgia-** Atlanta
- **Illinois-** Chicago (2)
- **Maryland-** Baltimore (2)
- **Massachusetts-** Boston (3)
- **Michigan-** Detroit
- **Minnesota-** Rochester
- **Missouri-** Kansas City. St. Louis
- **New Jersy-** New Brunswick
- **New York-** New York (3), Rosedale
- **North Carolina-** Durham
- **Ohio-** Cleveland
- **Oregon**- Portland
- **Pennsylvania-**Philadelphia, Pittsburg
- **South Carolina-** Charleston, Greenville
- **Texas-** Austin, Dallas
- **Utah-** Salt Lake City
- **Virginia-** Falls Church, Richmond
- **Washington-**Seattle

TRITON-CM (nucresiran; gene silencer)

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular events, on additional assessments of cardiovascular events and/or death, and on patient-reported health status and health-related quality of life
Primary endpoint	Assess whether treatment with nucresiran reduces the risk of death and recurrent cardiovascular events (cardiovascular hospitalizations and urgent heart failure visits)
Key eligibility criteria	- Medical history of heart failure, NT-proBNP >300 ng/L and < 8,500 ng/L. - If afib, screening NT-proBNP >600 ng/L and <8500 ng/L. - No prior or current TTR-lowering therapy - Stabilizer use is allowed
Number of patients	1750
Study Drug	Subcutaneous (under the skin) injection every 6 months
Chance of receiving study drug?	2/3 (66.7% chance) will receive nucresiran
How long?	Up to 5 years
Website	https://alnylam-sponsor-trials.xogene.com/trials/7052903

Recruiting TRITON-CM Countries (as of 7/22/26)

Amyloidosis Research Consortium

Recruiting TRITON-CM US Centers (as of 7/22/26)

Recruiting Centers:

- **California**-La Jolla, Stanford
- **Connecticut-**Norwich
- **District of Columbia-** Washington D.C.
- **Florida-** Brandon, Miami
- **Georgia-** Atlanta, Gainesville, Tucker
- **Illinois-** Evanston
- **Indiana-** Indianapolis (2)
- **Kansas-** Kansas City
- **Maryland-**Baltimore
- **Massachusetts-** Boston (2)
- **Michigan-**Detroit
- **Minnesota-** Rochester
- **Missouri**- St. Louis
- **New York-** Manhasset, New York (3) Bronx
- **North Carolina-** Charlotte
- **Ohio-** Cleveland
- **Oregon-** Portland
- **Pennsylvania-** Lancaster, Philadelphia
- **South Carolina-** Charleston
- **Texas-** Dallas, Houston, Plano
- **Utah-** Salt Lake City
- **Virginia-** Charlottesville**,** Falls Church, Norfolk, Richmond
- **Washington-** Spokane

TRITON-PN (nucresiran; gene silencer)

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (TRITON-PN)
Primary endpoint	Determine the efficacy of nucresiran in patients with hATTR-PN. Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Key eligibility criteria	Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive) Has a Karnofsky Performance Status (KPS) of ≥60%
Number of patients	125
Study Drug	Subcutaneous (under the skin) injection every 3 months; and then q6 in the ext.
Chance of receiving study drug?	No placebo approved vutrisiran compared to the study drug nucresiran
How long?	18 months
Website	https://alnylam-sponsor-trials.xogene.com/trials/7223203

Recruiting TRITON-PN Countries (as of 7/22/26)

Amyloidosis Research Consortium



Recruiting TRITON-PN US Centers (as of 7/22/26)

Recruiting Centers:

- **Colorado-** Aurora
- **Illinois-** Chicago
- **Maryland-** Baltimore
- **Massachusetts-** Boston
- **Minnesota-** Rochester
- **New York-** New York
- **North Carolina-**Chapel Hill
- **Texas-** Dallas

MAGNITUDE [nexiguran ziclumeran (nex-z, NTLA-2001); CRISPR gene editing]

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy and safety of nex-z in patients with ATTR-CM
Primary endpoint	Assess whether treatment with nex-z reduces the risk of cardiovascular related events (death, urgent heart failure visits, and cardiovascular hospitalizations)
Key eligibility criteria	- Medical history of heart failure, NT-proBNP >600 pg/mL and < 10,000 pg/mL - No treatment with patisiran (Onpattro), inotersen (Tegsedi), or eplontersen (Wainua) w/in 12 months prior to enrollment - No prior experience with vutrisiran (Amvuttra) - No history of liver disease
Number of patients	1200
Study Drug	1 time infusion
Chance of receiving study drug?	2/3 (67% chance) will receive nex-z 1/3 (33% chance) will receive placebo
How long?	18 months to ~5 years
Website	https://www.magnitudestudy.com/

Recruiting Global MAGNITUDE Countries (as of 7/22/26)

Amyloidosis Research Consortium



Recruiting MAGNITUDE-CM US Centers (as of 07/22/26)

Amyloidosis Research Consortium

Recruiting Centers:

- **Arizona-** Tucson
- **California-** Los Angeles (2), Palo Alto, San Diego
- **Colorado-** Denver
- **Connecticut-** New Haven
- **District of Columbia-** Washington DC
- **Florida-** Jacksonville, Weston
- **Georgia-** Atlanta
- **Illinois-** Chicago
- **Indiana-** Indianapolis
- **Kentucky-** Lexington
- **Maryland-** Baltimore
- **Massachusetts-** Boston (2)
- **Michigan-** Ann Arbor, Detroit
- **Minnesota-** Rochester
- **Missouri-** Kansas City
- **North Carolina-** Durham
- **New York-** New York (2)
- **Ohio-** Cleveland, Columbus
- **Oregon-** Portland
- **Pennsylvania-** Philadelphia, Pittsburgh (x2)
- **South Carolina-** Charleston
- **Texas-** Dallas (2), Houston (2), Plano
- **Virginia-** Falls Church, Richmond

MAGNITUDE-2 [nexiguran ziclumeran (nex-z, NTLA-2001); CRISPR gene editing]

ATTR-PN (hereditary only)

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy and safety of nex-z in patients with ATTR-PN
Primary endpoint	Assess the impact of a single dose of nex-z on neuropathy. measured by the Modified Neuropathy Impairment Score +7 (mNIS+7)
Key eligibility criteria	- Diagnosis of ATTRv-PN, without advanced heart failure - Able to care for themselves, though may require occasional assistance - No prior treatment with patisiran (Onpattro), vutrisiran (Amvuttra), inotersen (Tegsedi), or eplontersen (Wainua) - No history of liver disease
Number of patients	60
Study Drug	1 time infusion
Chance of receiving study drug?	1/2 (50% chance) will receive nex-z, 1/2 (50% chance) will receive placebo; opportunity for crossover
How long?	18 months

Recruiting Global MAGNITUDE-2 Countries (as of 7/22/26)

Amyloidosis Research Consortium



CLEOPATTRA (Coramitug; NNC6019-0001); anti-amyloid fibril

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Currently Recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate whether treatment with coramitug can help reduce the risk of heart-related death and illness in participants with ATTR-CM
Primary endpoint	Composite measure of cardiovascular deaths and recurrent cardiovascular events (cardiovascular hospitalizations and urgent heart failure visits)
Key Eligibility Criteria	- Cardiac amyloid infiltration, increased left ventricular wall thickness, and chronic heart failure requiring treatment with loop diuretic - NT-proBNP ≥1000 pg/mL at screening - Current or previous participation (dosing with active treatment) in a study for an investigational ATTR depleting drug or ATTR gene editing therapy
Number of patients	1280
Study Drug	Intravenous (into a vein) infusions every 4 weeks
Chance of receiving study drug?	1/2 (50% chance) will receive coramitug, 1/2 (50%) will receive placebo
How long?	Up to approximately 4 years
Website	https://www.novonordisk-trials.com/trials-conditions/all-trials-v2/NN6019-4958.html

Recruiting CLEOPATTRA Countries (as of 7/22/26)

Amyloidosis Research Consortium



Recruiting CLEOPATTRA US Centers (as of 7/22/26)

Amyloidosis Research Consortium

Recruiting Centers:

- **California-** Pasadena, San Francisco, Santa Rosa
- **Connecticut-** New Haven
- **District of Columbia-** Washington D.C.
- **Georgia-** Gainesville
- **Hawaii-** Honolulu
- **Illinois-** Glenview
- **Indiana-** Indianapolis
- **Louisiana-** New Orleans
- **Maryland-** Baltimore
- **Massachusetts-** Boston (2)
- **Michigan- Ann Arbor, Detroit**,Farmington Hills
- **Minnesota-** Rochester
- **Missouri-** Kansas City, St. Louis
- **Nebraska-** Omaha
- **New York-** New York(4), Bronx, Manhasset, Rosedale
- **Ohio-** Cincinnati, Cleveland
- **Pennsylvania-** Abington Philadelphia
- **South Carolina-** Greenville
- **Tennessee-** Nashville
- **Texas-** Austin (2) Houston
- **Virginia** Falls Church, Norfolk, Richmond
- **Washington-** Spokane

Upcoming Milestones for Novel ATTR Therapies in 2026

Amyloidosis Research



TTR Stabilizers	Pfizer	Tafamidis CM (Vyndaqel/Vyndamax)	Approved
	BridgeBio	**Acoramidis (Attruby) CM**	**Approved**
		Acoramidis ATTRv Carriers	P3 Recruiting
	Corino	Tolcapone	P1 Complete
Knockdown TTR	Alnylam	Patisiran (Onpattro) PN	Approved
		Vutrisiran (Amvuttra) PN	Approved
		Vutrisiran (Amvuttra) CM	Approved
		Nucresiran CM	P3 Recruiting
		Nucresiran PN	P3 Recruiting
	~~Ionis~~	~~Inotersen (Tegsedi) PN~~	~~Approved~~
	Ionis / AZ	Eplontersen (Wainua) PN	Approved
		Eplontersen CM	P3 Primary Endpoint not met
	Intellia	Nex-z (NTLA-2001) CM	P3 on hold
		Nex-z (NTLA-2001) PN	P3 on hold
Anti-fibril agents	Novo Nordisk	Coramitug CM (fka NNC6019-0001)	P3 Recruiting
	Alexion/ AZ	**Cliramitug CM (fka ALXN2220, NI006)**	**P3 results 2027**
	BridgeBio	Depleter (TBD)	P1 expected 2027-2028

Last Update July 2026

ASCEND-ATTR (acoramidis; TTR stabilizer)

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Planned, not yet recruiting
Study Phase	Phase 4
Purpose of the study	Investigate the long-term effects of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM using two types of imaging, cardiac MRI and echocardiograms
Primary endpoint	Assess the effect of acoramidis in how well the heart pumps blood after 36 months of treatment, compared with the start of the study
Key eligibility criteria	- 18 to 80 years old - NYHA Class I/II; estimated glomerular filtration rate (eGFR) ≥40 mL/min/1.73m2; left ventricular ejection fraction (LVEF) >35%; left ventricular (LV) wall thickness ≥12 mm - People who have mild or no symptoms from their heart condition, have reasonably good kidney function, their heart is still pumping relatively well, and the heart muscle is thicker than norma - No prior or current treatment with acoramidis
Number of patients	150
Study Drug	Daily tablets, twice a day
Chance of receiving study drug?	100%; all participants will receive acoramidis
How long?	38 months

DepleTTR-CM (ALXN2220; amyloid depleter)

ATTR-CM (wildtype or hereditary)

Amyloidosis Research Consortium

	Active, not recruiting
Study Phase	Phase 3
Purpose of the study	Evaluate the efficacy and safety of ALXN2220 in patients with ATTR-CM
Primary endpoint	Assess whether treatment with ALXN2220 reduces the risk of all cause mortality and cardiovascular clinical events
Key eligibility criteria	-History of heart failure, NT-proBNP >2000 pg/mL -No prior treatment with an ATTR amyloid depleter, but patients may be on locally approved standard of care therapy
Number of patients	1181
Study Drug	Intravenous (into a vein) infusions every 4 weeks
Chance of receiving study drug?	2/3 (67% chance) will receive ALXN2220 1/3 (33% chance) will receive placebo
How long?	2-4 years

Q: How long does FDA approval take after Phase 3?

Amyloidosis Research Consortium

Answer: Approval timelines can vary, many steps along the way

Factors that can influence timelines:

- FDA Advisory Committees (if needed)
- Priority Review Designation
- Breakthrough Therapy and Fast Track Designation
- Quality and Completeness of Submission
- FDA Resource Allocation and Review Capacity
- Communication and Information Requests

Other Recruiting and Planned Clinical studies

Amyloidosis Research Consortium

	Study Name/Description	Clinicaltrials.gov link
Imaging Trials	CATI: Test-retest Study With [18F]Florbetaben in Cardiac Amyloidosis	https://clinicaltrials.gov/study/NCT06790394
	EPIC-TTR: PET/CT Imaging in Carriers of TTR Mutations	https://clinicaltrials.gov/study/NCT07591038
	TRACE: PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels	https://clinicaltrials.gov/study/NCT07538518
	Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis	https://clinicaltrials.gov/study/NCT05758493
Single center trials	CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study *(Charlotte, NC)*	https://clinicaltrials.gov/study/NCT06096675
	Exercise Training in Transthyretin Cardiac Amyloidosis *(Boston, MA)*	https://clinicaltrials.gov/study/NCT05797857
	Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study *(Dallas, TX)*	https://clinicaltrials.gov/study/NCT07196839
Observational Studies	Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers	https://clinicaltrials.gov/study/NCT05489549
	Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry	https://clinicaltrials.gov/study/NCT05974644
	Canadian Registry for Amyloidosis Research	https://amyloidregistry.ca/home
	ACO-MONITOR: Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM *(Austria, Germany, Italy)*	https://clinicaltrials.gov/study/NCT07557147
Company sponsored registries and real world evidence studies	AstraZeneca: Non-interventional Study of Patients With ATTR Amyloidosis (MaesTTRo)	https://clinicaltrials.gov/study/NCT06465810
	Alnylam: A Global Observational Study of Patients With ATTR Amyloidosis (ConTTRibute)	https://clinicaltrials.gov/study/NCT04561518
	Alnylam: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting (DemonsTTRate)	https://clinicaltrials.gov/study/NCT07358078

How to find clinical trials

- You can find and stay informed of clinical trials a few different ways:
  - Clinicaltrials.gov
  - Talk to your healthcare provider
  - Follow patient organizations like ARC, ASG, etc.
  - Sign up for My Amyloidosis Pathfinder (MAP)

Amyloidosis Research Consortium



Discover Personalized Treatment Centers & Clinical Trials for Your Amyloidosis

myamyloidosispathfinder.org

map

POWERED BY

Amyloidosis Research Consortium

ARC TALKS
WEBINAR SERIES

ATTR Clinical Trial Updates

Thank you for joining us today. Please take a few minutes to fill out the post webinar survey.